What is Rawsome?
Rawsome operates at the intersection of holistic health and consumer packaged goods, specializing in a diverse portfolio of CBD-infused products. Their catalog, which includes tinctures, gummies, balms, and roll-ons, is formulated with organic ingredients to address specific consumer needs such as anxiety management, joint pain relief, and dermatological support. By prioritizing product purity and customer-centric service, Rawsome has carved out a distinct market position, appealing to a demographic increasingly seeking natural, plant-based alternatives for daily wellness maintenance. The company's commitment to transparency and quality control serves as a cornerstone of its brand identity in a sector often scrutinized for regulatory compliance and ingredient integrity.
How much funding has Rawsome raised?
Rawsome has raised a total of $323K across 2 funding rounds:
Debt
$150K
Debt
$173K
Debt (2020): $150K with participation from PPP
Debt (2021): $173K led by PPP
Key Investors in Rawsome
PPP
Public-Private Partnership
What's next for Rawsome?
With this late-stage capital, Rawsome is poised to transition into a phase of accelerated market penetration and infrastructure optimization. The strategic allocation of these funds will likely focus on scaling supply chain efficiencies, enhancing distribution channels, and potentially diversifying the product pipeline to meet shifting consumer preferences. As the regulatory environment for CBD continues to mature, Rawsome's ability to maintain high standards of production while scaling its operations will be critical. The company is well-positioned to leverage its current momentum to capture a larger share of the wellness market, provided it continues to navigate the complexities of the CBD industry with its established focus on quality and consumer trust.
See full Rawsome company page
